Adult-Use
Tracking legal status, market access, and regulatory developments across 28 European countries — with market data from Prohibition Partners.
Europe's largest cannabis market. First major EU economy to legalise adult use.
Europe's most mature cannabis tolerance policy, now transitioning to formal regulation.
Europe's largest untapped medical market — entering permanent regulation in 2026.
Legal medical market tightly controlled through military production.
Post-telemedicine-ban recovery: the EU's most complete regulatory risk case study.
Cannabis clubs operate in a legal grey zone while national regulation stalls.
Europe's largest cannabis exporter and a growing medical market.
Medical legal since 2013; emerging as a significant EU export producer.
From pilot to permanent: Denmark's medical market transitions in 2026.
Southern EU export hub with a growing domestic medical market.
First EU member state to legalise adult-use cannabis — December 2021.
Europe's second-largest medical market, driven by private telehealth clinics.
Medical legal and adult-use pilot underway in major cities.
Restricted to pharmaceutical products and magistral preparations only.
Restricted pilot programme for three qualifying conditions since 2019.
Restricted to pharmaceutical products; personal possession tolerated below 3g.
Personal cannabis legalised 2023; commercial retail not yet in place.
Medical access legalised August 2024 — a significant emerging Eastern European market.
Established export sector with ~70 licensed producers; under government review.
Progressive new framework passed July 2025 — one of the most open medical cannabis laws in Europe.
Medical cannabis legal since 2015 but market growth severely stalled by bureaucracy and high costs.
Legal framework exists but no patient access pathway has been established in practice.
Extremely narrow 2013 legalisation limited to sub-0.2% THC products. No practical patient access.
Framework legalised in 2019 but industry slow to implement — no patients have received treatment.
Medical cannabis accessible only via a complex special permit process through the State Agency of Medicines.
Strictly controlled unlicensed medicine. Special permit required from Finnish Medicines Agency Fimea.
Rigorous individual licence process via the Swedish Medical Products Agency. Patient numbers slowly growing.
Access via approval exemption from the Norwegian Medicines Agency. Hospital pharmacy distribution only.
As of 2026, Germany, Malta, and Luxembourg have legalised adult-use cannabis. Germany (April 2024) is the most significant, being the first major EU economy to do so. Malta (December 2021) was the first EU member state. Luxembourg legalised personal possession and home cultivation in 2023.
Germany is by far Europe's largest medical cannabis market at an estimated $976.9M in 2025, growing to $1.42B in 2026 (Prohibition Partners). The UK is Europe's second-largest medical market at £297.9M in 2026.
There is no EU-wide cannabis regulation. Each member state regulates cannabis independently. Three EU member states (Germany, Malta, Luxembourg) have legalised adult-use cannabis, while over a dozen have established medical programmes. Recreational cannabis remains illegal in most of Europe.
Poland's November 2024 telemedicine restrictions — which caused a 54% drop in prescriptions in just two months — established a risk model for other European markets that rely heavily on teleclinics, particularly Germany and the UK. Both markets are being monitored for similar regulatory action.